Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Ocular Therapeutix Inc. (NASDAQ:OCUL) is a biopharmaceutical company that develops and commercializes therapies for retinal ...

A mix of expected sequels and out-of-nowhere indie gems made 2025 a joy.

Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

New study reveals prediabetes remission can cut heart disease death risk by 58% through targeted lifestyle changes that keep ...

Benzodiazepine use during pregnancy is associated with a 20% higher risk for preterm birth and a 6% increased risk for small ...

The authors of a new Australian study say they have identified a set of 32 genetic variants that increase the likelihood of ...

Well, another year of soaking up much of what the entertainment world had to offer is just about in the books. I’ve compiled a baker’s dozen of titles that I enjoyed, a list extremely heavy on ...

Clinical trials continue to shape metastatic breast cancer treatment, making therapies safer, more tolerable, and more ...

Exercise improves quality of life and sleep in ovarian cancer patients, with moderate and significant benefits, respectively. Methodological variability and high heterogeneity in trials highlight the ...

New York State Psychiatric Institute and Columbia University Medical Center investigators, with co-authors across additional ...